Kyowa Kirin's Crysvita conditionally OK'd in Europe of rare musculoskeletal disorder in children

Kyowa Kirin's Crysvita conditionally OK'd in Europe of rare musculoskeletal disorder in children  Seeking Alpha Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease  EIN News (press release) Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in ...  PR Newswire UK (press release)Full coverage

Read More ...
Kyowa Kirin's Crysvita conditionally OK'd in Europe of rare musculoskeletal disorder in children published February 23, 2018 at 11:09PM. Original Source Link : https://seekingalpha.com/news/3333867-kyowa-kirins-crysvita-conditionally-okd-europe-rare-musculoskeletal-disorder-children

loading...